Condition
ADHD NOS
Total Trials
2
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
2 treatments under study, led by Atomoxetine
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
Termination Rate
0.0%
0 terminated out of 2 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
100%
2 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
2Total
Phase 4 (2)
Trial Status
Completed2
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (2)
Research Network
Common Treatments
- Atomoxetine1
- Strattera Atomoxetine1
Active Sponsors
- Massachusetts General Hospital2
- Eli Lilly and Company1
- McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.1
Top Investigators
Massachusetts General Hospital
Massachusetts General Hospital